Real-world efficacy and safety of Erenumab: a prospective study of 80 patients in a specialized headache center
暂无分享,去创建一个
[1] E. V. Ekusheva,et al. The use of the monoclonal antibody Erenumab in patients with chronic migraine in real clinical experience , 2021, Russian neurological journal.
[2] G. Terwindt,et al. Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study , 2021, European Journal of Neurology.
[3] A. Straube,et al. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany , 2021, The Journal of Headache and Pain.
[4] M. Filippi,et al. Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study , 2020, Headache.
[5] P. Cortelli,et al. Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center , 2020, Neurological Sciences.
[6] S. Sacco,et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy , 2020, The Journal of Headache and Pain.
[7] S. Sacco,et al. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal , 2019, The journal of headache and pain.
[8] P. Barbanti,et al. Erenumab: from scientific evidence to clinical practice—the first Italian real-life data , 2019, Neurological Sciences.
[9] S. Tepper. CGRP and headache: a brief review , 2019, Neurological Sciences.
[10] S. Sacco,et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention , 2019, The Journal of Headache and Pain.
[11] P. Martelletti. Erenumab is effective in reducing migraine frequency and improving physical functioning , 2018, BMJ Evidence-Based Medicine.
[12] D. Dodick,et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine , 2018, Cephalalgia : an international journal of headache.
[13] M. Naprienko,et al. Strategies for Improving the Efficacy of Treatment of Chronic Migraine , 2017, Neuroscience and Behavioral Physiology.
[14] L. Bloudek,et al. Systematic Review of Migraine Prophylaxis Adherence and Persistence , 2014, Journal of managed care pharmacy : JMCP.
[15] R. Ohrbach,et al. The International Classification of Headache Disorders, 3rd edition (beta version) , 2013, Cephalalgia : an international journal of headache.
[16] David Cella,et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.